caspofungin

(redirected from Cancidas)

caspofungin

 [kas″po-fun´jin]
an antifungal used as the acetate salt in the treatment of invasive aspergillosis, administered intravenously.

caspofungin

(kas'pō-fŭn-jin),
A member of the echinocandin class of antifungal compounds targeting the fungal cell wall.

caspofungin

/cas·po·fun·gin/ (kas″po-fun´jin) an antifungal used as the acetate salt in the treatment of invasive aspergillosis.

caspofungin

a beta-glucan synthase inhibitor used as a broad spectrum antifungal agent.
References in periodicals archive ?
12 billion; Invanz, used to treat a variety of bacterial infections and generating $544 million in sales; and Cancidas, prescribed for treatment of candidemia and other Candida infections, with annual sales of $540 million.
Caspofungin exclusive supply medicines, CANCIDAS articles 50 and 71 mg and posaconazole 100 mg Noxafil article.
Cancidas was approved in January 2001 as a treatment for fungal infections.
Decision Resources (Waltham, MA), one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, said that, because of their improvements in safety and efficacy, physicians are increasingly prescribing next-generation antifungals such as Pfizer's Vfend, Schering-Plough's Noxafil, Merck's Cancidas, Astellas' Mycamine and Pfizer's Eraxis.
Merck & Company, Whitehouse Station, NJ, received FDA approval to market Cancidas (caspofungin acetate) Intravenous Infusion for patients who are unresponsive to or cannot tolerate standard therapies for the invasive form of aspergillosis.
Acquisition of drug Cancidas 50 and 70 mg vial destined for the Health Area No.
Merck currently has one anti-fungal drug on the market, Cancidas, but is one of the top makers of vaccines to prevent infectious diseases.
Comment: Cancidas inhibits the synthesis of an essential component of the fungal cell wall.
since a panel recommended that the Food and Drug Administration approve its experimental drug Cancidas for use in fighting a rare but often fatal infection known as aspergillosis in patients who have not responded to or could not tolerate other treatments.
Merck & Company, Whitehouse Station, NJ, announced the Antiviral Advisory Committee of the US Food and Drug Administration (FDA) unanimously recommended approval of Cancidas (caspofungin acetate), the company's investigational intravenous antifungal medicine used for the treatment of invasive aspergillosis in patients who did not respond to or were intolerant of other antifungal therapies.
428 6% Vytorin cholesterol $1,882 -7% Cozaar/Hyzaar high blood pressure $1,663 -21% Janumet diabetes $1,363 43% Isentress HIV/AIDS $1,359 25% Nasonex allergic rhinitis $1,286 5% Gardasil HPV vaccine $1,209 22% Varivax chickenpox vaccine $1,202 -13% Temodar oncology $935 -12% Fosamax postmenopausal $855 -8% osteoporosis Peglntron hepatitic C $657 -11% Rotateq rotavirus vaccine $651 25% Cancidas antifungal $640 5% Maxalt migraine $639 16% Nuvaring contraception $623 11% Clarinex allergic rhinitis $621 -6% Primaxin antibiotic $515 -16% Account for 73% of total pharma sales, up from 72% in 2010
Cancidas (caspofungin) is indicated for intravenous infusion in patients with aspergillus infection who are refractory to or intolerant of other treatments.